Une nouvelle analyse modélisée renforce le potentiel de TECVAYLI®▼ (teclistamab) associé au daratumumab pour redéfinir les perspectives de survie à long terme dans le myélome multiple en rechute/réfractaire dans les premières lignes de traitement

Data ReadoutpositiveTECVAYLIdaratumumabPositive

AI Analysis

Summary

Johnson & Johnson announced positive Phase 3 MajesTEC-3 data for TECVAYLI (teclistamab) in combination with daratumumab in relapsed/refractory multiple myeloma patients, demonstrating sustained disease control and prolonged survival in earlier lines of treatment.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Phase 3 MajesTEC-3 data showed sustained disease control and prolonged survival with teclistamab plus daratumumab in relapsed/refractory multiple myeloma patients

Importance:7/10

Sentiment:

0.70

multiple myelomaPhase 3data readoutsurvival benefitrelapsed/refractory

Related Companies

$JNJ

Read the original article

Published by GlobeNewswire Pharma on September 28, 2026 5:44 PM

Read Original